Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.24.2
Commitments and Contingencies (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 28, 2024
USD ($)
Oct. 27, 2023
USD ($)
Jul. 31, 2019
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2020
USD ($)
milestone
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2023
USD ($)
Aug. 14, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Feb. 03, 2020
USD ($)
Other Commitments [Line Items]                          
Accrued expenses and other current liabilities       $ 7,383,000     $ 4,172,000            
Contingent consideration       12,500,000     0            
Payment received     $ 2,000,000                    
Period after public launch to terminate agreement     3 years                    
Percentage of net present value of royalty payments     75.00%                    
Aevi                          
Other Commitments [Line Items]                          
Milestone payment       0                  
AlmataBio Transaction                          
Other Commitments [Line Items]                          
Payments to acquire productive assets $ 7,500,000     7,500,000                  
Milestone payment due upon first patient dosed in a Phase 2 trial       5,000,000                  
Aevi                          
Other Commitments [Line Items]                          
Number of milestones | milestone         2                
Milestone payment due upon first patient dosed in a Phase 2 trial         $ 6,500,000                
Milestone One | AlmataBio Transaction                          
Other Commitments [Line Items]                          
Milestone payment due upon first patient dosed in a Phase 2 trial 5,000,000                        
Milestone One | Aevi                          
Other Commitments [Line Items]                          
Milestone payment due upon first patient dosed in a Phase 2 trial                         $ 2,000,000
Milestone One | AVTX-009                          
Other Commitments [Line Items]                          
Contingent consideration       7,500,000                  
Milestone Two | AlmataBio Transaction                          
Other Commitments [Line Items]                          
Milestone payment due upon first patient dosed in a Phase 2 trial $ 15,000,000                        
Milestone Two | Aevi                          
Other Commitments [Line Items]                          
Milestone payment due upon first patient dosed in a Phase 2 trial                         $ 4,500,000
Milestone Two | AVTX-009                          
Other Commitments [Line Items]                          
Contingent consideration       5,000,000                  
Lilly License Agreement | AVTX-009 Lilly License Agreement                          
Other Commitments [Line Items]                          
Milestone payments       70,000,000                  
Lilly License Agreement | AVTX-009 Lilly License Agreement | Milestone One                          
Other Commitments [Line Items]                          
Maximum aggregate milestone payment       720,000,000                  
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement                          
Other Commitments [Line Items]                          
Upfront license fee                       $ 10,000,000  
Percent of payments received from sublicensing                       30.00%  
Research and development expense       0                  
Cumulative expense recognized to date       0                  
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone One                          
Other Commitments [Line Items]                          
Maximum aggregate milestone payment                       $ 112,500,000  
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone Two                          
Other Commitments [Line Items]                          
Maximum aggregate milestone payment                       $ 75,000,000  
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement                          
Other Commitments [Line Items]                          
Upfront license fee                 $ 400,000        
Research and development expense       0                  
Cumulative expense recognized to date       0                  
Patent costs                 500,000        
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone One                          
Other Commitments [Line Items]                          
Maximum aggregate milestone payment                 24,200,000        
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone Two                          
Other Commitments [Line Items]                          
Maximum aggregate milestone payment                 $ 50,000,000        
Astellas Pharma, Inc. (Astellas) | AVTX-006 Astellas License Agreement                          
Other Commitments [Line Items]                          
Maximum aggregate milestone payment       5,500,000                  
Upfront license fee       500,000                  
Research and development expense       0                  
Cumulative expense recognized to date       500,000                  
ES | AVTX-406 License Assignment                          
Other Commitments [Line Items]                          
Revenue recognized from milestones to date       0                  
ES | Milestone One | AVTX-406 License Assignment                          
Other Commitments [Line Items]                          
Maximum proceeds from milestones                   $ 6,000,000      
ES | Milestone Two | AVTX-406 License Assignment                          
Other Commitments [Line Items]                          
Maximum proceeds from milestones                   $ 20,000,000      
Alto | AVTX-301 Out-License                          
Other Commitments [Line Items]                          
Maximum proceeds from milestones                     $ 18,600,000    
Revenue recognized from milestones to date       0                  
AUG Therapeutics, LLC | Purchase Agreement | AVTX-800 Series Asset Sale                          
Other Commitments [Line Items]                          
Upfront payment paid   $ 200,000                      
Asset acquisition consideration transferred, liabilities   $ 400,000                      
Contingent milestone upfront payment percentage   0.20                      
Contingent milestone payment   $ 15,000,000                      
Maximum potential payments   $ 45,000,000                      
TRIS Pharma | Karbinal Agreement                          
Other Commitments [Line Items]                          
Minimum quantity required | unit           70,000              
Make whole payment per unit (in dollars per share) | $ / shares           $ 30              
Apollo AP43 Limited                          
Other Commitments [Line Items]                          
Payments for legal settlements       $ 200,000                  
Accrued expenses and other current liabilities             $ 200,000            
Apollo AP43 Limited | Maximum                          
Other Commitments [Line Items]                          
Estimate of possible loss               $ 800,000